To identify KRAS-specific vulnerabilities in lung cancer, we performed functional genomic screens in primary tumor cells derived from a genetically engineered mouse model of lung cancer driven by the activation of the Kras G12D allele and the loss of p53 (KrasLSL-G12D, Trp53fl/fl; KP)15,16 (Fig. 1a). The gene discussed is KRAS; the disease is lung carcinoma.